As a medical professional with expertise in cardiology, I can provide you with information on the treatment of ventricular tachycardia (VT). The choice of drug for treating VT can vary depending on the specific circumstances and the patient's medical history. However, in the context of acute monomorphic VT, the preferred first-line treatment is often an IV antiarrhythmic drug. In the United States, the IV antiarrhythmic drugs available for the suppression of acute monomorphic VT include procainamide, lidocaine, and amiodarone. Additionally, beta-adrenergic blocking agents such as metoprolol, esmolol, and propranolol are also used. Among these options, amiodarone is often considered the drug of choice for the pharmacological conversion of acute monomorphic VT, especially when other treatments are ineffective or contraindicated. It is a versatile drug with multiple mechanisms of action, including antiarrhythmic, vasodilatory, and beta-blocking effects. read more >>

In the United Sates, the intravenous (IV) antiarrhythmic drugs available for suppression of acute monomorphic VT are limited to procainamide, lidocaine, and amiodarone, along with the beta-adrenergic blocking agents metoprolol, esmolol, and propranolol.read more >>